Fig. 3From: Design, synthesis, in vitro anticancer, molecular docking and SAR studies of new series of pyrrolo[2,3-d]pyrimidine derivativesThe molecular binding of compound 14a with the active site of a P53 and b Bcl2, and compound 17 with the active site of c P53 and d Bcl2Back to article page